Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
• Market outline
• Types of Krabbe disease

PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 06: MARKET SIZING
• Market definition
• Market sizing
• Market size and forecast

PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: PIPELINE ANALYSIS

PART 09: MARKET SEGMENTATION BY THERAPY
• Segmentation by therapy
• Comparison by therapy
• Global Krabbe disease treatment market by anticonvulsants
• Global Krabbe disease treatment market by muscle relaxants
• Global Krabbe disease treatment market by HSCT
• Global Krabbe disease treatment market by others
• Market opportunity by therapy

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Krabbe disease treatment market in Americas
• Krabbe disease treatment market in EMEA
• Krabbe disease treatment market in APAC
• Key leading countries
• Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 14: MARKET TRENDS
• Emergence of pharmacological chaperone therapy
• Gene technology in therapy

PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption

PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• GlaxoSmithKline
• Johnson & Johnson
• Novartis

PART 17: APPENDIX
• List of abbreviations

[List of Exhibits]
Exhibit 01: Types of Krabbe disease
Exhibit 02: Parent market
Exhibit 03: Global rare diseases treatment market: Segmentation
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition: Inclusions and exclusions checklist
Exhibit 07: Market size
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global Krabbe disease treatment market 2017-2022 ($ millions)
Exhibit 10: Global Krabbe disease treatment market: Year over year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trials for global Krabbe disease treatment market
Exhibit 20: Global Krabbe disease treatment market by therapy 2017-2022 (% share)
Exhibit 21: Comparison by therapy
Exhibit 22: Global Krabbe disease treatment market by anticonvulsants 2017-2022 ($ millions)
Exhibit 23: Global Krabbe disease treatment market by anticonvulsants: Year over year growth 2018-2022 (%)
Exhibit 24: Global Krabbe disease treatment market by muscle relaxants 2017-2022 ($ millions)
Exhibit 25: Global Krabbe disease treatment market by muscle relaxants: Year over year growth 2018-2022 (%)
Exhibit 26: Global Krabbe disease treatment market by HSCT 2017-2022 ($ millions)
Exhibit 27: Global Krabbe disease treatment market by HSCT: Year over year growth 2018-2022 (%)
Exhibit 28: Global Krabbe disease treatment market by others 2017-2022 ($ millions)
Exhibit 29: Global Krabbe disease treatment market by others: Year over year growth 2018-2022 (%)
Exhibit 30: Market opportunity by therapy
Exhibit 31: Customer landscape
Exhibit 32: Global Krabbe disease treatment market by region 2017-2022 (% share)
Exhibit 33: Regional comparison
Exhibit 34: Krabbe disease treatment market in Americas 2017-2022 ($ millions)
Exhibit 35: Krabbe disease treatment market in Americas: Year over year growth 2018-2022 (%)
Exhibit 36: Krabbe disease treatment market in EMEA 2017-2022 ($ millions)
Exhibit 37: Krabbe disease treatment market in EMEA: Year over year growth 2018-2022 (%)
Exhibit 38: Krabbe disease treatment market in APAC 2017-2022 ($ millions)
Exhibit 39: Krabbe disease treatment market in APAC: Year over year growth 2018-2022 (%)
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Some long-term complications in HSCT patients
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: GlaxoSmithKline: Overview
Exhibit 49: GlaxoSmithKline: Business segments
Exhibit 50: GlaxoSmithKline: Organizational developments
Exhibit 51: GlaxoSmithKline: Geographic focus
Exhibit 52: Johnson & Johnson: Segment focus
Exhibit 53: GlaxoSmithKline: Key offerings
Exhibit 54: GlaxoSmithKline: Key customers
Exhibit 55: Johnson & Johnson: Overview
Exhibit 56: Johnson & Johnson: Business segments
Exhibit 57: Johnson & Johnson: Organizational developments
Exhibit 58: Johnson & Johnson: Geographic focus
Exhibit 59: Johnson & Johnson: Segment focus
Exhibit 60: Johnson & Johnson: Key offerings
Exhibit 61: Johnson & Johnson: Key customers
Exhibit 62: Novartis: Overview
Exhibit 63: Novartis: Business segments
Exhibit 64: Novartis: Organizational developments
Exhibit 65: Novartis: Geographic focus
Exhibit 66: Novartis: Segment focus
Exhibit 67: Novartis: Key offerings
Exhibit 68: Novartis: Key customers